Polymer nanoparticles mediated codelivery of antimiR-10b and antimiR-21 for achieving triple negative breast cancer...

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer with limited therapeutic options.
• MicroRNAs (miRNAs) like miR-21 (anti-apoptosis) and miR-10b (metastasis) play critical roles in TNBC progression.
• Developing targeted therapies to simultaneously address these pathways is crucial for effective treatment.

Purpose of the Study:

• To investigate the therapeutic potential of simultaneously antagonizing miR-21 and miR-10b in TNBC.
• To develop and evaluate polymer nanoparticles (NPs) for targeted delivery of antisense oligonucleotides against miR-21 and miR-10b.
• To assess the efficacy of this dual-targeting strategy in vitro and in vivo models of TNBC.

Main Methods:

• Synthesis of poly(lactic-co-glycolic acid)-b-poly(ethylene glycol) (PLGA-b-PEG) polymer nanoparticles co-loaded with antisense-miR-21 and antisense-miR-10b.
• Evaluation of NP characteristics including cellular uptake, serum stability, and drug release profile.
• Assessment of miRNA function blockade in TNBC cells and tumor xenografts using molecular imaging.
• In vivo efficacy studies in mice bearing TNBC tumors, comparing targeted NPs with control NPs.

Main Results:

• The synthesized NPs effectively delivered antisense oligonucleotides, leading to synchronous blocking of endogenous miR-21 and miR-10b in TNBC cells.
• Targeted NPs demonstrated significant reduction in tumor growth in vivo at a low dose (0.15 mg/kg).
• A 40% reduction in tumor growth was observed compared to scramble peptide-conjugated NPs, highlighting the efficacy of dual-targeting.

Conclusions:

• Simultaneous antagonism of miR-21 and miR-10b using targeted polymer nanoparticles is an effective strategy for treating metastatic TNBC.
• This multitargeting approach demonstrates significant therapeutic potential by inhibiting both anti-apoptosis and metastasis.
• The developed NPs represent a promising new therapeutic option for TNBC, warranting further clinical investigation.